Drugs by condition
Drugs approved for postpartum depression
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
1
Still marketed, NDA or BLA
Drug classes
1
Novel drugs
1
New molecular entities and new biologics
In development
3
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for postpartum depression.
- Zurzuvae (Zuranolone) · Biogen NovelPriority reviewAug 4, 2023
All approved drugs for postpartum depression, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator (1)
- Zurzuvae Zuranolone · Biogen · 2023
Drugs in development for postpartum depression
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- MI078Phase 32 trials
Nanjing Minova Pharmaceutical Co., Ltd. · Postpartum Depression (PPD), Postpartum Depression
- RE104Phase 23 trials
Reunion Neuroscience Inc · Adjustment Disorder, Generalized Anxiety Disorder, Postpartum Depression
- NORA520Phase 21 trial
TWi Biotechnology, Inc. · Depression, Postpartum, Postpartum Depression, Post-partum Depression
More on postpartum depression: recruiting trials · published research
Related in psychiatry: Depression (major depressive disorder) · Schizophrenia · Bipolar disorder · ADHD · Anxiety disorders · Insomnia · Opioid use disorder · Alcohol dependence · Smoking cessation · PTSD
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.